One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage All Access membership.
Explore Editage All Accesshttps://doi.org/10.1200/jco.2016.34.15_suppl.tps7079
Copy DOI Journal: Journal of Clinical Oncology |  Publication Date: May 20, 2016 |
Affiliation: Mayo Clinic, Délégation Paris 7, Hôpital Saint-Louis, Université Paris Cité, Ospedale Papa Giovanni XXIII, Imperial College London, Icahn School of Medicine at Mount Sinai, AZ Sint-Jan, Leipzig University, University of Chicago, Janssen (United States), Stanford University, Jewish General Hospital, University of Barcelona, University of Maryland, BaltimoreTPS7079Background: MF is a Philadelphia chromosome negative myeloproliferative neoplasm, with a relatively poor prognosis. Ruxolitinib, a JAK1/JAK2 inhibitor, is the only approved therapy for MF, a...
Sign-in/Register to access full text options 
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
